RBC Capital has made significant adjustments to its price targets (PT) for Sarepta Therapeutics ($SRPT), raising the PT to $157 and $185 at RBC and Barclays respectively, while reiterating an Outperform rating on Tesla ($TSLA) with a PT of $297. Furthermore, RBC Capital analysts suggest Tesla's Megapack battery storage business could potentially surpass the value of its car business, estimating the industry could generate $600B in annual revenues, with Tesla potentially capturing at least $90B from a 15% market share. This optimistic outlook on Tesla's utility battery business has sparked debate among investors and analysts.
So we really are going to claim that a battery assembly business is worth 20x revenues…?! You’re not alone @TeslaBoomerMama https://t.co/wiVqBWuz1t
⚠️ JUST IN: *RBC CAPITAL SAYS TESLA MEGAPACK BUSINESS COULD BE WORTH 'SUBSTANTIALLY MORE' THAN CAR BUSINESS $TSLA https://t.co/GNeqxjDfK6
RBC Capital is wrong about Tesla. It’s not “Tesla’s utility battery business MAY be worth more than the car business”, it’s “Tesla’s utility battery business WILL be worth more than the car business” $TSLA https://t.co/yg6vSEmRBi
Analysts at RBC Capital believe Tesla's Megapack battery storage business could be worth substantially more than its standalone car business. "This could yield $600B in annual industry revenues; A 15% market share could mean at least $90B in Tesla-specific battery storage…
RBC Capital reiterated an Outperform rating and $297 PT on Tesla! 🔋🔋 https://t.co/69OGTur4c5 $TSLA #Tesla #Megapack #EnergyStorage https://t.co/GLtqmFOVuS
$SRPT PT raised to $185 at Barclays.
$SRPT PT raised to $157 at RBC